Commonwealth & 4th Global Wound Conference 2022
October 25, 2022
New paper published in Annals of Case Reports: Combining DEBRICHEM® treatment with NPWT
February 24, 2023
Peer-reviewed paper on DEBRICHEM® published in the Journal of Wound Care
November 1, 2022 News

A new peer-reviewed paper on our novel debriding agent DEBRICHEM® was published in the October edition of the Journal of Wound Care. 

The article is titled “A desiccation compound as a biofilm- and necrosis-removing agent: a case series” and showcases a series of 54 mostly large and hard-to-heal lesions of different aetiologies that were treated with a one-time application of DEBRICHEM®, followed by weekly dressing changes. 

Among the cases included, 22 were diagnosed as venous leg ulcers (VLUs), 20 as diabetic foot ulcers (DFUs), nine as post-traumatic, hard-to-heal lesions, two as vascular ulcers and one as an ischaemic ulcer.

Results:

  • Complete granulation was achieved by 50 (92.5%) out of 54 lesions in, on average, 36.2 days (range: 2–131 days). 
  • The biofilm and necroses generally came away from the underlying tissue within a few days. 
  • No antibiotics were administered during the original procedure. 
  • There were no adverse events related to treatment with DEBRICHEM®.


In some cases, the timeframe in which the results were obtained was relatively long; this is most likely because

  • the analysis included large and often deep (Wagner III and IV) lesions in patients with a high average age and several concomitant diseases; and
  • after a one-time application of DEBRICHEM®, wound treatment consisted of only Vaseline gauze, a material known to be suboptimal for wound healing purposes, this was done to ensure that any other product used did not impact the results.

Procedural pain was rated 1.9 on average (range: 0–5), with 15 patients (with diabetes) indicating no pain at all (due to neuropathy). The average level of pain on post‑procedural day 1 was rated as 0.2 (range: 0–2), with 48 patients scoring zero.

Patients and physicians were asked to compare DEBRICHEM® treatment to the patient’s most recent previous treatment:

  • For the patients, DEBRICHEM® was considered ‘substantially better’ by 36/54 (66.6%), ‘better’ by nine (16.7%), ‘similar’ by seven (13.0%) and ‘worse’ by two (3.7%). 
  • For the physician, these numbers were 45 (83.3%), five (9.3%), two and two (3.7% each), respectively. 

Click the link below to read the full article.

FULL ARTICLE: “A desiccation compound as a biofilm- and necrosis-removing agent: a case series” 

Peer-reviewed paper on DEBRICHEM® published in the Journal of Wound Care
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.